Eric Lefkofsky Bringing Cancer Treatment Up to Speed

Although cutting-edge technology is revolutionizing healthcare, the healthcare delivery system has been slow to advance. According to a recent article by Heidi Harris on TechNewsSpy.com, prominent web entrepreneur Eric Lefkofsky’s most recent venture, Tempus, is making waves in both the tech and medical communities with a tool set to transform cancer treatment and research through data-enabled precision medicine.

A Detroit native with a law degree from the University of Michigan, Eric Lefkofsky has made his career as a dotcom business mogul in Chicago and is perhaps best known as the co-founder of Groupon, along with Lightbank, InnerWorkings, and others. He has taught courses on technology in business at DePaul and Northwestern Universities, and currently teaches as an adjunct professor at the University of Chicago’s Booth School of Business.

Always a generous philanthropist, Lefkofsky has given millions to cancer research in his lifetime along with serving on the board of directors of Lurie’s Children’s Memorial Hospital in Chicago and giving to other educational, arts, and charitable causes. He decided to launch Tempus when he saw up-close the inadequacy of contemporary Electronic Health Records systems, and realized his tech skills could help.

Tempus is a platform operating out of Chicago which aims to transform the way cancer care – and eventually all healthcare – is delivered by collecting and analyzing molecular and clinical data, which doctors can then use to customize the most effective treatments, even personalizing care to individual patients. This large library of data can be shared with biotech companies, insurance companies, and clinicians to tailor the exact dosage and sequence of medication and other regimens.

Tempus could also prove to be a valuable tool in cancer research, which Harris says is increasingly “focusing on fighting the disease on the molecular and cellular levels.” As this molecular, genomic data is analyzed and paired with data from patients’ progress and outcome notes, researchers at universities, hospitals, and cancer centers will be better able to evaluate which medicines and treatments will be effective. With the help of companies like Tempus, patients and their families will receive the best available care.